In the following, we would like to update you on current changes in the regulatory framework (OECD, ICH and others), inform you on upcoming congresses (including where you can meet us in person) and add information on the company and recent novelties.

“In our own case”

Meet us in Cologne

The 47th Annual Meeting of the European Teratology Society and the 17th European Congress of Toxicologic Pathology are moving closer and will be held in parallel Sept 17-20 at the Maternushaus in Cologne. It would be a great opportunity to meet personally with Prof. Robert Klopfleisch and Dr. Geertje Lewin, to discuss questions and projects, share
Read More

Changes in Company Management

Lars Mecklenburg,  co-founder of PRECLINICAL SCIENCE, has decided to discontinue consulting. Lars will no longer accept new clients but will be available for existing clients regarding previous projects. His reponsibilities around pathology have been transferred to Robert Klopfleisch and his duties around preclinical drug development projects have been taken over by Roman Föll and Geertje
Read More

Alternative Advances in Zoological and Medical Terminology

The discovery and detailed scientific description of new zoological and medical entities is a slow and work intensive process. After the scientific description of the genus Rhinogradientia (by Gerolf Steiner, 1961) and the species Steinlaus (Petrophaga lorioti, 1976), finally the medical world now faces the first detailed work on etiology, epidemiology, clinical symptoms and treatment
Read More

Dates / Congresses

Joint ETS/ESTP Annual Meeting 2019

We are proud to announce that ETS (European Teratology Society) and ESTP (European Society of Toxicologic Pathology) will join their annual meetings in 2019 and welcome you September 17 – 20, 2019 in Cologne. You can meet us there!  
Read More

Legislative change

New implementation or update of OECD Guidelines

Over the last 3 months, a variety of OECD guidelines for in vitro toxicity testing has been newly implemented or updated. The current versions can be downloaded via the PDF link. OECD 431: In vitro skin corrosion: reconstructed human epidermis (RHE) test method  PDF OECD 432: In Vitro 3T3 NRU Phototoxicity Test  PDF OECD 439: In Vitro
Read More

New EMA Draft Guideline for Environmental Risk Assessment of Medicinal Products

At the end of 2018, the European Medicines Agency published the new draft Guideline on the environmental risk assessment of medicinal products for human use  for public consultation. Deadline for comments will be 30 June 2019.
Read More

Nonclinical Safety Testing Guideline S11

ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) issued the first draft of guideline S11 on Nonclinical Safety Testing in Support of Development of Pediatric Medicines in September 2018.
Read More

Worth knowing from the authorities

Products for parenteral diet in preterm babies – need of light protection

The following warning was recently issued by the Drug Commission of the German Medical Association concerning parenteral diet in preterm babies. Due to the immaturity of the intestinal tract and immune system, liver metabolism and detoxifying mechanisms, parenteral diet has to be protected from light during storage and treatment. Otherwise these drugs, containing amino acids
Read More

EFSA Dietary Reference Values

The European Food Safety Authority published their “Dietary Reference Values for Nutrients” in a Summary Report. Dietary reference values (DRVs) is an umbrella term for the complete set of nutrient reference values which include population reference intakes (PRIs), the average requirements (ARs), adequate intakes (AIs) and reference intake (RIs) ranges for macronutrients. In 2005, the European
Read More

BfS Annual Report 2017/18 published

The Federal Office for Radiation Protection (BfS) issued its Annual Report 2017/2018, including updates on prevention of UV-associated diseases, on the situation of radiation protection for patients in medicine and on occupational radiation protection.     
Read More

From the science community

Dysgeusia after drug treatment

A not so uncommon side effect after drug treatment are changes in taste (dysgeusia) or loss of taste (ageusia). A wide range of drugs may cause these this sensual alteration, including but not limited to anticholinergic drugs, anti-diabetics, sedativa, antibiotics, dopamine receptor antagonists and certain anti-hypertensive drugs. Examples Hypogeusia: Amphotericin B, Carbamazepin, Cisplatin, Diltiazem, Carboplatin, Levodopa,
Read More

Start typing and press Enter to search